-
Notable Insider Buys of the Past Week: Foot Locker, Icahn Enterprises, Kraft Heinz And More
Saturday, December 5, 2020 - 2:43pm | 978Read More...Insider buying can be an encouraging signal for potential investors when markets face uncertainty. This past week, some insiders added to their stakes in REITs, a specialty retailer and a packaged foods giant. Some insiders were making return trips to the buy window to increase their stakes....
-
Aegis Says FDA's Outlook 'Not As Negative As People Think' on Amarin
Monday, October 14, 2013 - 1:30pm | 373Read More...The outlook of Amarin shares appeared bleak following an FDA release over concerns of the Vascepa drug. On October 16, an advisory committee will convene to decide if Amarin's lead drug will help with the treatment of mixed dyslipidemia. On Monday, Aegis Capital released a statement expressing...
-
Jefferies' Updates 6/3
Friday, June 3, 2011 - 9:58am | 1674Read More...Jefferies initiated coverage of Cisco Systems (NASDAQ: CSCO) with a Hold rating. At the same time, Jefferies put its price target on the company's stock to $15.75. In a research report published today, Jefferies states, "We believe it's too early for investors to commit to the stock as we're still...
-
Jefferies Maintains Buy on Amarin
Friday, June 3, 2011 - 8:15am | 109Read More...Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "A competitor has raised questions raised over the validity of the statistical analyses used in the MARINE and ANCHOR studies, but for reasons we outline below, we remain...
-
Jefferies Maintains Buy on Amarin
Tuesday, May 31, 2011 - 8:37am | 100Read More...Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "We had an opportunity to spend time with AMRN senior management to discuss potential scenarios for a pharma partnership or acquisition, AMR101 regulatory filings, and the CV...
-
Jefferies Maintains Buy on Amarin
Friday, May 27, 2011 - 9:14am | 89Read More...Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "The National Heart, Lung, and Blood Institute announced discontinuation of the AIM-HIGH trial, concluding that niacin with statin would not show benefit over statin alone in...
-
Jefferies Maintains Buy on Amarin Corp. (AMRN)
Thursday, February 10, 2011 - 9:33am | 88Read More...Jefferies is out with its report today on Amarin Corp. (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "We believe AMR101 offers robust efficacy for hyperlipidemia, lowering triglycerides without raising cholesterol like Lovaza. With a cleaner profile and potentially a...
